HCPCS J7676: Pentamidine Isethionate Inhalation, Compounded 300 mg - OpenPayer

Summary & Overview

HCPCS J7676: Pentamidine Isethionate Inhalation, Compounded 300 mg

HCPCS Level II code J7676 represents pentamidine isethionate inhalation solution as a compounded unit dose (per 300 mg) administered through durable medical equipment. This code captures a specific inhaled antimicrobial preparation used in respiratory therapy and prophylaxis, and its proper coding affects coverage determination, DME billing, and medication administration records nationally.

Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of clinical context for inhaled pentamidine, typical sites of service (home and outpatient settings using DME), and the billing context for a compounded unit-dose inhalation product. The publication summarizes coverage considerations, common modifier usage patterns provided in the input, and relevant service-line implications.

The analysis provides benchmarks and reference points for claims and reimbursement processes where available, highlights policy and documentation elements that influence payment, and clarifies the role of DME in administering this medication. Data not available in the input is noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ7676HCPCS Level IIinhalation therapypentamidinecompounded medicationdurable medical equipmenthome infusionambulatory care

Billing Code Overview

HCPCS Level II code J7676 describes pentamidine isethionate, inhalation solution, compounded product, supplied in unit dose form, per 300 mg, and administered through durable medical equipment (DME). This indicates a compounded inhaled antimicrobial formulation delivered via a nebulizer or other DME respiratory device.

Service type: Inhalation antimicrobial therapy (compounded), medication administration via DME

Typical site of service: Home health or outpatient/home infusion setting using DME (nebulizer or inhalation device)

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A 52-year-old patient with advanced human immunodeficiency virus (HIV) and a history of recurrent Pneumocystis jirovecii pneumonia (PJP) presents for prophylactic inhaled therapy. The patient is unable to tolerate oral or intravenous pentamidine alternatives due to gastrointestinal side effects and limited venous access. The pulmonology clinic orders inhaled pentamidine isethionate, compounded as unit-dose vials of 300 mg, to be administered via a nebulizer provided as durable medical equipment (DME).

The clinical workflow includes the following steps:

The prescribing clinician documents the indication (PJP prophylaxis or treatment), weight-based dosing considerations, and any drug allergies in the medical record.
The pharmacy compounds the J7676 product into unit-dose 300 mg inhalation solution and labels it for nebulizer use; compounding records and lot numbers are recorded.
The DME supplier provides and documents the nebulizer device and patient education materials for home administration if applicable.
A nurse or respiratory therapist observes the first administration in clinic to confirm technique and monitors for acute adverse effects (bronchospasm, cough, hypotension).
Subsequent administrations occur in clinic, outpatient infusion center, or at home as ordered; the provider documents administration date, lot number, route (inhalation via nebulizer), and any immediate reactions.
Billing uses HCPCS code J7676 for the unit-dose 300 mg compounded inhalation solution, with appropriate modifiers appended when clinically indicated and supported by documentation.

HCPCS J0221: Alglucosidase alfa (Lumizyme) Injection, 10 mg

HCPCS-J1120-ACETAZOLAMIDE-INJECTION-500MG

HCPCS Level II J1120: Injection, Acetazolamide Sodium, up to 500 mg

HCPCS-J7294-YEARLY-VAGINAL-CONTRACEPTIVE-SYSTEM-SEGESTERONE-ETHINYL-ESTRADIOL

HCPCS J7294: Yearly Vaginal Contraceptive System (Segesterone/Ethinyl Estradiol)

HCPCS-J0282-AMIODARONE-30MG-INJECTION-INTRAVENOUS-ANTIARRHYTHMIC

HCPCS J0282: Amiodarone Hydrochloride Injection, 30 mg

HCPCS-J7174-FITUSIRAN-INJECTION-04-MG

HCPCS J7174: Fitusiran Injection, 0.04 mg

HCPCS-J0760-COLCHICINE-INJECTION-1MG

HCPCS J0760: Injection, Colchicine, per 1 mg

HCPCS-J2786-RESLIZUMAB-INJECTION-1MG

HCPCS Level II J2786: Reslizumab Injection, 1 mg

HCPCS-J7599-IMMUNOSUPPRESSIVE-DRUG-NOT-OTHERWISE-CLASSIFIED

HCPCS J7599: Immunosuppressive Drug, Not Otherwise Classified

HCPCS-J1890-CEPHALOTHIN-INJECTION-1G

HCPCS J1890: Injection, Cephalothin Sodium, up to 1 Gram

HCPCS-J7609-ALBUTEROL-INHALATION-SOLUTION-COMPOUNDED-UNIT-DOSE-1MG

HCPCS Level II J7609: Albuterol Inhalation Solution, Compounded, Unit Dose, 1 mg

Showing 1–10 of 991

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when additional work or resources were required beyond typical administration (extensive documentation required).
`23`	Unusual anesthesia	Rarely used for inhalation pentamidine; use only if general anesthesia was medically necessary for administration.
`52`	Reduced services	Use when a planned administration was partially reduced or not completed, with documentation of reason.
`53`	Discontinued procedure	Use when administration was started but halted due to adverse event or patient intolerance.
`54`	Surgical care only	Not typically applicable; included when another provider performs surgical portion separate from administration.
`55`	Postoperative management only	Not typically applicable to this drug administration.
`56`	Preoperative management only	Not typically applicable to this drug administration.
`62`	Two surgeons	Generally not applicable; use only if two qualified practitioners were required for administration.
`AS`	Ambulatory surgical center (facility)	Use when the administration occurs in an ASC and reporting facility-related circumstances is required.
`CO`	Services provided by a resident under teaching physician not involving direct patient care	Use per payer rules when resident provided services without direct attending involvement.
`CQ`	Service furnished under an outpatient therapeutic infusion plan of care (used by certain payers)	Use when item is part of an established outpatient infusion/therapeutic plan if payer requires.
`QX`	Service performed by an individual practitioner with a valid modifier QX (e.g., CRNA supervision)	Use when applicable under payer rules for supervising practitioner arrangements.
`QY`	Qualified nonphysician practitioner service	Use when a qualified nonphysician practitioner (e.g., nurse practitioner) independently provides the administration per payer rules.
`JZ`	No return of unused drug to stock (zero waste)	Use when the unit dose vial is opened and no portion is returned; documents disposal/wastage.

Taxonomy Code	Specialty	Notes
207RC0000X	Pulmonary Disease	Pulmonologists prescribe and supervise inhaled pentamidine for PJP prophylaxis/treatment.
208000000X	Infectious Disease	Infectious disease specialists manage prophylaxis and dosing in immunocompromised patients.
363LP0200X	Nurse Practitioner - Pulmonology	NPs in pulmonary practices frequently manage follow-up and medication administration.
207L00000X	Pulmonary Critical Care	Critical care specialists may coordinate inhaled therapy in hospitalized or high-risk patients.
364S00000X	Registered Nurse	RNs or respiratory therapists administer and monitor inhaled treatments in clinic or infusion settings.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`B59`	Pneumocystosis	Primary indication for inhaled pentamidine for treatment of Pneumocystis jirovecii pneumonia.
`B20`	Human immunodeficiency virus [HIV] disease	Common underlying condition indicating need for PJP prophylaxis or treatment with inhaled pentamidine.
`D70.9`	Neutropenia, unspecified	Immunosuppressed patients with neutropenia may require PJP prophylaxis when other agents are contraindicated.
`D89.9`	Disorder involving the immune mechanism, unspecified	Represents other immunodeficiency states where prophylactic inhaled pentamidine may be indicated.
`T88.7XXA`	Unspecified adverse effect of drug or medicament, initial encounter	Used if patient experiences adverse reaction during or after inhaled pentamidine administration and initial encounter is documented.
`J96.00`	Acute respiratory failure, unspecified whether with hypoxia or hypercapnia	Used if severe respiratory compromise occurs related to underlying disease or medication reaction during treatment.
`Z79.899`	Other long term (current) drug therapy	May be used to indicate ongoing prophylactic antimicrobial therapy when appropriate.
`Z51.81`	Encounter for therapeutic drug level monitoring	Used when therapeutic monitoring or drug-related follow-up is performed as part of management.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`94640`	Pressurized or non-pressurized inhalation treatment for acute airway obstruction or for sputum induction for diagnostic purposes, including administration of nebulized medications	May be used to report the nebulizer administration session when payer requires a procedure code for supervision/administration of inhaled therapy.
`94664`	Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device	Used when a clinician or respiratory therapist provides education and evaluates the patients technique with the nebulizer for inhaled `J7676` therapy.
`99070`	Supplies and materials (except spectacles), provided by the physician over and above those usually included with the office visit	May be used by some payers to bill additional supplies associated with administration when allowed.
`99354`	Prolonged physician service in the office or other outpatient setting requiring direct patient contact beyond the usual service; first hour	Used when extended face-to-face time is required for administration, monitoring, or management due to complications or complexity.
`94621`	Pulmonary stress testing; spirometry, including graphic record, maximum voluntary ventilation, and arterial blood gas, when performed	May be performed before initiation in select patients to assess baseline respiratory function (reported when clinically performed).

OpenPayer